Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 4Thoracic 1Sarcoma 1Plasma cell 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Sarcoma, Endometrial Stromal 1Sarcoma 1Rhabdomyosarcoma 1Recurrence 1Prostatic Neoplasms 1Osteosarcoma 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Fibrosarcoma 1Dermatofibrosarcoma 1Breast Neoplasms 1Bone Neoplasms 1Bone Diseases 1

Interventions

pembrolizumab 9Gemcitabine 9Cyclophosphamide 8Radiotherapy 7Carboplatin 7Paclitaxel 6Cisplatin 6Trastuzumab 5Irinotecan 5Doxorubicin 5Docetaxel 5Peripheral Blood Stem Cell Transplantation 4Filgrastim 4Capecitabine 4poly ICLC 3pazopanib 3liposomal doxorubicin 3durvalumab 3atezolizumab 3Therapeutics 3Taxes 3Surveys and Questionnaires 3Radiation 3Polymerase Chain Reaction 3Oncolytic Virotherapy 3Letrozole 3Injections 3Fulvestrant 3Fluorodeoxyglucose F18 3Flow Cytometry 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × saracatinib × Sarcoma × Clear all
NCT00558272 2013-05-27

Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease

AstraZeneca

Phase 2 Completed
139 enrolled 23 charts
BreastGenitourinarySarcoma

Bone Diseases, Bone Neoplasms, Breast Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡